1. Home
  2. HUBS vs PTGX Comparison

HUBS vs PTGX Comparison

Compare HUBS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HubSpot Inc.

HUBS

HubSpot Inc.

HOLD

Current Price

$217.09

Market Cap

9.5B

Sector

Technology

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$138.25

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUBS
PTGX
Founded
2005
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.5B
8.5B
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
HUBS
PTGX
Price
$217.09
$138.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
32
13
Target Price
$435.19
$108.23
AVG Volume (30 Days)
1.3M
761.7K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
855.56
N/A
EPS
0.62
0.05
Revenue
$375,612,000.00
N/A
Revenue This Year
$20.46
$874.25
Revenue Next Year
$16.01
N/A
P/E Ratio
$374.90
$2,685.40
Revenue Growth
N/A
N/A
52 Week Low
$169.63
$50.49
52 Week High
$568.16
$143.29

Technical Indicators

Market Signals
Indicator
HUBS
PTGX
Relative Strength Index (RSI) 57.26 61.49
Support Level $209.40 $94.48
Resistance Level $225.58 $141.10
Average True Range (ATR) 12.55 6.64
MACD 3.71 -0.42
Stochastic Oscillator 69.59 68.67

Price Performance

Historical Comparison
HUBS
PTGX

About HUBS HubSpot Inc.

HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Share on Social Networks: